Search Results
Your search for all items matches 34717 pages
Showing 11001 - 11050UICC Welcomes New President, President-Elect, and Board of Directors for 2020–2022
At the recent General Assembly of the Union for International Cancer Control (UICC), which was held virtually for the first time, Anil D’Cruz, MD, of India, was welcomed as the organization’s new President. Full member organizations also elected the 2020–2022 Board of Directors, including...
Recurrence-Free Survival Benefit Maintained With Adjuvant Nivolumab vs Ipilimumab in Stage IIIB–IIIC and IV Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, and colleagues, 4-year results of the CheckMate 238 trial show continued benefit of adjuvant nivolumab vs ipilimumab in recurrence-free survival and metastasis-free...
Breast Cancer and Radiation Researcher David Gius, MD, PhD, Joins Mays Cancer Center
David Gius, MD, PhD, a breast cancer and radiation researcher, has joined the Mays Cancer Center, home to The University of Texas Health San Antonio MD Anderson. He was recruited to the Mays Cancer Center from the Robert H. Lurie Comprehensive Cancer Center at Northwestern University with a $6...
The Secret History of Cancer Chemotherapy
“The summons came in the middle of the night. He was awake at the first harsh jangle of the telephone…. Always a light sleeper, Lieutenant Colonel Stewart Francis Alexander attributed the trait to his father, an old-fashioned family practitioner whose response to every late-night distress call was...
A Gritty Journey Into a Rare Cancer and Back
Over the past decade, a prolific number of cancer memoirs have been published, and some have been award-winning bestsellers. When entering a crowded genre, it is best to have something that sets your story apart. Judith Dwyer Fugate did just that with a memoir about a rare tumor that has rarely if...
Cleveland Clinic Announces Oncology Staff Appointments
Cleveland Clinic recently announced the following additions to its oncology staff: Ruth Keri, PhD, has joined Cleveland Clinic Lerner Research Institute Department of Cancer Biology. She will study breast cancer, focusing on identifying the molecular processes that control the formation of breast...
UCLA Researchers’ Efforts in Melanoma Receive $13M Boost From NIH
University of California, Los Angeles (UCLA) researchers have received a $13 million grant from the National Institutes of Health (NIH) to find new ways to overcome melanoma resistance to some of the most promising targeted therapies and immunotherapies. There have been significant advancements in...
The Gut, Our Choices, and Gynecologic Cancers: Investigating an Unlikely Trio
Disturbance of the gut microbial metabolism is thought to be the root cause of human diseases. Bacteria, viruses, and fungi affect their human hosts in numerous ways. There is evidence to support the theory that microbes, through their genetic makeup, gene products, and metabolites, play a role in...
Expert Point of View: Bartosz Chmielowski, MD, PhD
The invited discussant of LEAP-004, Bartosz Chmielowski, MD, PhD, Associate Clinical Professor at the University of California Los Angeles Jonsson Comprehensive Cancer Center, commented: “The response rate of 21% was quite impressive for this patient population. Patients previously treated with an...
Advanced Melanoma: Lenvatinib Plus Pembrolizumab After Disease Progression on Anti–PD-1 Therapy
Checkpoint inhibitors can be lifesaving for many patients with advanced melanoma, but those who experience disease progression currently have few treatment options. The combination of a tyrosine kinase inhibitor and an anti–PD-1 agent may offer some hope in this setting, according to a study of...
Pay-for-Performance Program to Reimburse Oncology Practices for Prescribing Evidence-Based Cancer Drugs
A pay-for-performance program that offers enhanced reimbursement to oncology practices for prescribing high-quality, evidence-based cancer drugs increased use of these drugs without significantly changing total spending on care, Penn Medicine researchers reported in a study published in the Journal ...
Expert Point of View: Salah-Eddin Al-Batran, MD
Salah-Eddin Al-Batran, MD, Director of the Institute of Clinical Cancer Research and Director of GI Oncology at Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, commented on KEYNOTE-590 at a press briefing. Dr. Al-Batran noted that the prognosis for advanced esophageal cancer is...
Dana-Farber/Harvard Cancer Center Wins Federal Grant to Accelerate Ovarian Cancer Research
Dana-Farber/Harvard Cancer Center (DF/HCC) has been awarded a $12 million grant from the National Cancer Institute (NCI) to bring promising ovarian cancer research from the laboratory to clinical practice. The highly competitive Specialized Programs of Research Excellence (SPORE) grant will help...
First-Line Pembrolizumab Plus Chemotherapy Improves Survival in Esophageal Cancer
As first-line therapy for advanced esophageal cancer, pembrolizumab added to chemotherapy improved overall survival in the KEYNOTE-590 population. Not only did patients with high PD-L1 expression benefit, the value of checkpoint inhibition was observed for the whole population, the trial’s...
Panel With Diverse Perspectives Explores Strategies to Reduce Costs for Cancer Care
“Imagine that it’s 5 years from now, and we are in a situation where the cost of cancer care has flattened, and costs are even going down,” said Clifford Goodman, PhD, a Senior Vice President at the Lewin Group, turning to a panel of oncology and policy experts at his side. “What policies got us...
Isabelle Tabah-Fisch, MD, Drug Researcher, Industry Executive, Dies at 64
Isabelle Tabah-Fisch, MD, a medical oncologist in Paris who contributed greatly to drug development, died August 28, 2020, at age 64. An announcement about Dr. Tabah-Fisch’s death was made by GamaMabs, where she served as Chief Medical Officer until her retirement in March 2020. Under her...
Susan G. Komen to Present 2020 Brinker Awards for Scientific Distinction
Susan G. Komen is recognizing two widely respected and innovative breast cancer researchers—Donald McDonnell, PhD, and Laura Esserman, MD, MBA—as this year’s recipients of their highest scientific honor, the Brinker Awards. Established by Komen in 1992, the awards recognize advances in the...
Lesley Solomon, MBA, of Dana-Farber, Receives Extraordinary Women Advancing Healthcare Award
Lesley Solomon, MBA, Senior Vice President for Innovation and Chief Innovation Officer at Dana-Farber Cancer Institute, has received the 2020 Extraordinary Women Advancing Healthcare Award from The Commonwealth Institute, a nonprofit organization devoted to advancing women in leadership positions....
Daughter of an Orthopedic Surgeon, Abigail T. Berman, MD, Finds Radiation Oncology Intriguing
Radiation oncologist Abigail T. Berman, MD, was born and reared in Philadelphia, the daughter of an orthopedic surgeon whose passion for his work was an early influence on her decision to pursue a career in medicine. “My father absolutely adored his job and worked very hard, which inspired me to...
City of Hope Launches Innovative Support Model for Employers
City of Hope in Duarte, California, announced the formal launch of AccessHope, a wholly owned subsidiary dedicated to serving employers and their health-care partners. Instead of requiring patients to travel to City of Hope, AccessHope exports insights from National Cancer Institute–level...
ASTRO Calls for Changes to Benefits Manager Policy That Disrupts Patient/Physician Decision-Making for Cancer Radiotherapy
Radiation oncologists have expressed serious concerns about a new private insurance coverage policy that could undermine patient-centered care for two of the most common cancers in the United States. Leaders of the American Society for Radiation Oncology (ASTRO) urge eviCore, a radiation oncology...
Dana-Farber Announces Center for Salivary and Rare Head and Neck Cancers
Dana-Farber Cancer Institute has launched the Center for Salivary and Rare Head and Neck Cancers to treat patients with rare and occasionally aggressive cancers arising from the head and neck. The Center is among the first in the country specifically dedicated to the care and therapeutic research...
How Telemedicine Is Impacting Oncology Care During the COVID-19 Pandemic
The expansion of telemedicine has been one of the most important developments during the COVID-19 pandemic. Here, we discuss some of the legal and ethical dimensions of expanding telemedicine services in oncology practices. As Royce et al discussed in a recent JAMA Oncology article, Congress...
2020 NIH Director’s Early Independence Awards Announced
The National Institutes of Health (NIH) Director’s Early Independence Award, established in 2010, is part of the High-Risk, High-Reward Research program managed by the Common Fund. The award provides an opportunity for exceptional junior scientists to skip the traditional postdoc and start an...
Surgical and Radiation Oncology in Elderly Patients With Cancer
As one might expect, the focus on older patients developed in surgical and radiation oncology at the same time as in medical oncology. As we have done in our overview of medical oncology, we may recognize a prehistory, past history, and present history in surgical and radiation geriatric oncology....
Mountainside Medical Center Appoints Co–Medical Director
Mountainside Medical Center has announced that Lori Leslie, MD, has been named Co–Medical Director of the hospital’s Cancer Program, which is affiliated with John Theurer Cancer Center at Hackensack University Medical Center. Dr. Leslie joins the Cancer Program leadership, serving alongside Donna...
Cancer in Older Adults: The History of Geriatric Oncology, Part 2: 1990–2020
In part 1 of this three-part article, which was published in the October 10, 2020, issue of The ASCO Post, we chronicled the progress made in geriatric oncology up to the decade of the 1990s, which saw an explosion of research activity in the study of aging and cancer. In part 2, we review the...
James K. McCloskey II, MD, Named Division Chief of the Division of Leukemia at John Theurer Cancer Center
James K. McCloskey II, MD, was named Division Chief of the Division of Leukemia at Hackensack Meridian John Theurer Cancer Center (JTCC), part of Hackensack University Medical Center. Dr. McCloskey previously served as Interim Chief for the Division of Leukemia and will continue in his role as...
FDA Awards Six Grants to Fund New Clinical Trials of Medical Products for Treatment of Rare Diseases
The U.S. Food and Drug Administration (FDA) announced it has awarded six new clinical trial research grants to principal investigators from academia and industry, totaling more than $16 million over the next 4 years. These grants, awarded through the Congressionally funded Orphan Products Grants...
Expert Point of View: Chiara Cremolini, MD, PhD
The KEYNOTE-177 invited discussant, Chiara Cremolini, MD, PhD, of the University of Pisa, Italy, welcomed the patient-reported outcomes of the study, noting that such data are frequently missing. “Unfortunately, quality of life is an often-disregarded issue in colorectal cancer clinical trials,”...
First-Line Pembrolizumab in Metastatic Colorectal Cancer: Quality of Life Also Improved
In KEYNOTE-177, the anti–PD-L1 antibody pembrolizumab reduced the risk of disease progression by 40% vs chemotherapy in a targeted subset of previously untreated patients with metastatic colorectal cancer. Now, in terms of health-related quality of life, pembrolizumab is also the clear favorite,...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Activity of the KRAS G12C Inhibitor Sotorasib in KRAS G12C–Mutant Advanced Solid Tumors
As reported inThe New England Journal of Medicine by David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, a phase I trial (CodeBreak 100) has shown activity of the oral KRAS G12C inhibitor sotorasib in heavily pretreated patients with KRAS G12C–mutant...
UICC Launches New Program at the Start of Breast Cancer Awareness Month
As the cancer community marks Breast Cancer Awareness Month this October, the Union for International Cancer Control (UICC) is starting a new 5-year program aimed at accelerating progress in breast cancer control. “While the incidence of breast cancer is generally higher in more developed regions, ...
Capmatinib Active in Advanced NSCLC With MET Exon 14 Skipping Mutations
As reported inThe New England Journal of Medicine by Jürgen Wolf, MD, of the Center for Integrated Oncology, University Hospital Cologne and University of Cologne, and colleagues, the phase II GEOMETRY mono-1 trial has shown durable responses with the selective MET inhibitor capmatinib in patients...
Lourdes A. Báezconde-Garbanati, PhD, Receives AACR Distinguished Lectureship on Cancer Health Disparities
The American Association for Cancer Research (AACR) awarded Lourdes A. Báezconde-Garbanati, PhD, the 2020 AACR Distinguished Lectureship on the Science of Cancer Health Disparities. Dr. Báezconde-Garbanati presented her award lecture, “Optimizing Engagement to Reduce Disparities Among...
Anthony Fauci, MD, to Receive Lifetime Achievement Award From National Minority Quality Forum
The National Minority Quality Forum announced that Anthony Fauci, MD, will receive its 2020 Bernard J. Tyson Lifetime Achievement Award, which recognizes health-care leaders who have helped to decrease health disparities and to build sustainable healthy communities. Dr. Fauci—who has served as...
Yale Cancer Center Awarded NIH SPORE Grant for Head and Neck Cancer Research
Yale Cancer Center (YCC) researchers were awarded a 5-year, $11.7 million grant from the National Institutes of Health (NIH) to fund the Yale Head and Neck Cancer Specialized Program of Research Excellence (SPORE). The SPORE program harnesses the strengths of academic cancer centers by bringing...
Thinking Out of the Box to Advance the Management of Chronic Graft-vs-Host Disease
Over the past decade, the field of allogeneic hematopoietic cell transplantation has made great strides, evolving into a curative procedure for blood cancers that once were almost always fatal. However, chronic graft-vs-host disease, whose biologic etiology remains unclear, continues to be the...
Rutgers Cancer Institute of New Jersey Awarded $1.6M for Youth Science Program
Rutgers Cancer Institute of New Jersey has received a $1.6 million, 5-year grant from the National Cancer Institute to support the Rutgers Youth Enjoy Science (RUYES) Program. RUYES seeks to increase the diversity of the biomedical, cancer research workforce to reduce cancer disparities in New...
Expert Point of View: Henrik Grönberg, MD
Formal discussant of the -IPATential150 trial, Henrik Grönberg, MD, Professor at Karolinska Institute, Stockholm, found the study results intriguing, especially in the PTEN-loss patients. “Biomarkers are the wave of the future,” he said. “The study population was compared with an adequately...
Ipatasertib/Abiraterone Combination Shows Potential in Metastatic Castration-Resistant Prostate Cancer With PTEN Loss
Ipatasertib plus abiraterone plus prednisone achieved significantly superior radiographic progression–free survival and antitumor activity compared with placebo plus abiraterone plus prednisonein patients with metastatic castration-resistant prostate cancer and PTEN loss, according to the results...
Florida Surgeon Steven D. Wexner, MD, FACS, Elected Vice-Chair of Board of Regents of American College of Surgeons
Steven D. Wexner, MD, PhD (Hon), FACS, FRCS (Eng), FRCS (Ed), FRCSI (Hon), Hon FRCS (Glasg), was recently elected Vice-Chair of the Board of Regents of the American College of Surgeons (ACS) during the College’s virtual Clinical Congress 2020, held October 3–7. Dr. Wexner is Chair of the...
Expert Point of View: Henrik Grönberg, MD
Formal discussant of the PROfound trial, Henrik Grönberg, MD, of the Karolinska Institute, Stockholm, agreed that this was a practice-changing trial for select patients. “The patient population is representative, but the problem is the control group, which included patients who experienced disease ...
Olaparib Improves Outcomes in Metastatic Castration-Resistant Prostate Cancer With BRCA1/2 Alterations
The PARP inhibitor olaparib reduced the risk of death by 31% compared with a second hormonal treatment (enzalutamide or abiraterone) in men with metastatic castration-resistant prostate cancer characterized by BRCA1, BRCA2, or ATM mutations, in the final analysis of the phase III PROfound trial...
Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, Honored With Nobel Prize in Chemistry 2020
On October 7, 2020, The Royal Swedish Academy of Sciences announced that the Nobel Prize in Chemistry 2020 would be awarded to Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, “for the development of a method for genome editing,” the CRISPR/Cas9 genetic scissors. “There is enormous power...
2020 Nobel Prize in Physiology or Medicine Awarded to Team Who Discovered Hepatitis C Virus
This year’s Nobel Prize in Physiology or Medicine was awarded to three scientists who have made a decisive contribution to the treatment of blood-borne hepatitis, a major global health problem that causes cirrhosis and liver cancer in people around the world. Harvey J. Alter, MD; Michael Houghton,...
Early-Phase Study Reports Progress in Targeting KRAS-Mutated Tumors With Sotorasib
Although KRAS is one of the most frequently mutated oncogenes in human cancers, an almost 4-decade long search for drugs that hit this target has been elusive—until now. Sotorasib (formerly called AMG-510), a small-molecule inhibitor of the KRAS G12C mutation, demonstrated clinical activity and...
Expert Point of View: Roy S. Herbst, MD, PhD, FACP, FASCO
Invited discussant of the EMPOWER-Lung 1 trial, Roy S. Herbst, MD, PhD, FACP, FASCO, Chief, Medical Oncology, Yale Cancer Center, New Haven, Connecticut, pointed out the tremendous progress that has been made since 2000 in treating NSCLC. “In 2000, median survival for advanced NSCLC was 7.9...
EMPOWER-Lung 1 Trial: Cemiplimab Improves Survival Over Chemotherapy in Advanced NSCLC
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 presented several abstracts with good news for patients with lung cancer. Long-term follow-up of immunotherapies showed excellent survival, a promising new ALK inhibitor improved outcomes compared with the standard of care, the...
